Very Good Site citratone wrinkle cream The fund, called Action Potential Venture Capital, will complement the work of GSK’s Bioelectronics R&D unit, which was established in 2012 "after a two-year effort to seek out and engage the most promising researchers in this emerging area of science". The company believes miniaturised devices can be designed to read, change or generate electronic impulses that may help treat a multitude of disorders, including inflammatory bowel disease, rheumatoid arthritis, respiratory diseases and diabetes.
|